Skip to main content
Premium Trial:

Request an Annual Quote

Affy's Schiffman Steps Down; Quackenbush Joins Helicos' SAB; Strategic Diagnostics' CFO Resigns; Abbott Alumnus to Run IntegraGen's US Expansion; and Others

The headline for this article has been updated from a previous version, which incorrectly identified Robert Gottlieb as an ABI alumnus instead of an Abbott alumnus.
NEW YORK (GenomeWeb News) — Gregory Schiffman has left his various senior executive positions at Affymetrix to take on the role of senior vice president and chief financial officer at Dendreon, a Seattle-based drug developer.
Affymetrix said today that Schiffman resigned, effective immediately, from his posts as executive vice president, CFO, and treasurer, as well as other positions he holds at Affy subsidiaries.
The company said James Gibson, 37, will take over the role of principal accounting officer from his position as vice president of accounting and corporate controller. Gibson formerly served as director of finance and controller at Netflix.
Affy said it intends to start seeking candidates for the CFO and principal financial officer immediately.
Before working at Affymetrix, Schiffman held vice president positions at Applied Biosystems, Hewlett Packard, and IBM.

Next-generation sequencing company Helicos Biosciences said this week it has added John Quackenbush and David Liu to the company’s scientific advisory board.
Quackenbush is a professor of biostatistics and computational biology at the Dana-Farber Cancer Institute and is professor of biology and bioinformatics at the Harvard University’s School of Public Health.
Liu is professor of chemistry and chemical biology at Harvard University, and is an associate member of the Broad Institute of Harvard and Massachusetts Institute of Technology.

Bionovo this week said it has added Terry Speed to its scientific advisory board. Speed is a professor of statistics at the University of California, Berkeley, and is a senior principal research scientist and head of bioinformatics at the Walter and Eliza Hall Institute of Medical Research in Melbourne, Australia.
Speed also has served on the scientific advisory board for mathematical biosciences at Ohio State University at the US Department of Energy’s Joint Genome Institute.

Millennium Pharmaceuticals this week said Bob Tepper, president of its research and development division, will leave the company in the first quarter of 2007. Millennium said Tepper was one of the company’s founding members, having been there since 1994.
Millennium said it is currently seeking a successor.

Custom antibody designer Strategic Diagnostics on Thursday said Chief Financial Officer Anthony Simonetta has resigned to “pursue other opportunities.”
The company said it will begin a search for a new CFO immediately.

IntegraGen has appointed Robert Gottlieb to serve as CEO of the company’s US expansion effort, the firm said this week.
Gottlieb will take the helm at IntegraGen, Inc., which will be based in New York. He will continue to serve the parent company as vice president of global sales and marketing.
Gottlieb has worked at Abbott Laboratories, General Electric, Becton Dickinson, and Roche Diagnostics.     

Cambridge Antibody Technology this week said it has appointed Adrian Kemp to the post of general counsel. Kemp worked at AstraZeneca for ten years as a senior counsel and as an assistant secretary.

The Scan

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.

Study Highlights Pitfall of Large Gene Panels in Clinical Genomic Analysis

An analysis in Genetics in Medicine finds that as gene panels get larger, there is an increased chance of uncovering benign candidate variants.

Single-Cell Atlas of Drosophila Embryogenesis

A new paper in Science presents a single-cell atlas of fruit fly embryonic development over time.

Phage Cocktail Holds Promise for IBD

Researchers uncovered a combination phage therapy that targets Klebsiella pneumonia strains among individuals experiencing inflammatory bowel disease flare ups, as they report in Cell.